west
CLINICAL TRIALS
First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia
Recruiting
First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib (KO-539), a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML).
Est. Enrollment: 60 participants
info
The number of participants in a clinical study. The "estimated" enrollment is the
target number of participants the researchers need for the study.
Study Start Date: Sep 12, 2019
info
These are the dates the researchers think the study will start and end.
Study Completion Date: Dec 31, 2022
info
The "estimated" study completion date is the date the researchers think the last
participant in a clinical study was examined or received an intervention/treatment. This
is also the expected date that the study will be completed
Age: 18+ years
Gender: All
Study Description
expand_more
Study Details
expand_more
Questions?
Contact Us
A member of our team would love to assist you.
How Clinical Trials Work (800) 930-5159 Email usGet the latest thought leadership on AML delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.
Thanks to our HealthTree Community for AML Sponsors:
%20-%20smaller%20jpg_5093a115-769d-4cb8-99c4-e07244874f4d.jpg?alt=media){kind=logo}
Follow Us
Terms of Use and Privacy Policy Newsroom About Donations Find an AML Specialist Newsletter Learn Connect
Copyright © 2022 HealthTree Foundation. All Rights Reserved.
The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811
